Clinical Cancer Research, Vol 3, Issue 12 2355-2362, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Effects of a beta-human chorionic gonadotropin subunit immunogen administered in aqueous solution with a novel nonionic block copolymer adjuvant in patients with advanced cancer

PL Triozzi, VC Stevens, W Aldrich, J Powell, CW Todd and MJ Newman
The Ohio State University Comprehensive Cancer Center, 410 West 10th Ave, Columbus, Ohio 43210, USA.

The clinical and immunological effects of a vaccine consisting of CTP37, a synthetic peptide corresponding to the COOH-terminal peptide (CTP) of beta-human chorionic gonadotropin (beta-hCG) conjugated to diphtheria toxoid, combined with CRL 1005, a novel synthetic nonionic block copolymer adjuvant, were examined. Twenty-one patients with metastatic, nontrophoblastic cancers received up to four immunizations by i.m. injection of a fixed dose of CTP37 and escalating doses of CRL 1005. Doses of CRL 1005 adjuvant as high as 75 mg were administered with 1 mg of CTP37 without evidence of significant local or systemic toxicity. Immunizations resulted in the production of IgG antibody to beta-hCG. CRL 1005 doses of 3-25 mg appeared to be optimal for antibody induction. Immunizations also resulted in increases in the cellular response of peripheral blood mononuclear cells (PBMCs) to the unconjugated CTP, hCG, and diphtheria toxoid. Responding PBMCs specifically secreted the TH1-associated cytokines IFN-gamma and interleukin (IL)-2 as well as the TH2-associated IL-5 and IL-10. Increased expression of IFN gamma and IL-5 mRNAs by PBMCs 4 h after immunization was also observed. CRL 1005 administered with CTP37 in aqueous solution is well tolerated. The CTP37-CRL 1005 subunit vaccine has the capacity to stimulate potentially beneficial humoral and cellular immune responses in patients with advanced cancer.

This article has been cited by other articles:

				L.-Z. He, V. Ramakrishna, J. E. Connolly, X.-T. Wang, P. A. Smith, C. L. Jones, M. Valkova-Valchanova, A. Arunakumari, J. F. Treml, J. Goldstein, et al. A Novel Human Cancer Vaccine Elicits Cellular Responses to the Tumor-Associated Antigen, Human Chorionic Gonadotropin {beta} Clin. Cancer Res., March 15, 2004; 10(6): 1920 - 1927. [Abstract] [Full Text] [PDF]

				S. A. Butler and R. K. Iles Ectopic Human Chorionic Gonadotropin {beta} Secretion by Epithelial Tumors and Human Chorionic Gonadotropin {beta}-Induced Apoptosis in Kaposi's Sarcoma: Is There a Connection? Clin. Cancer Res., October 15, 2003; 9(13): 4666 - 4673. [Abstract] [Full Text] [PDF]

				H. M. Moulton, P. H. Yoshihara, D. H. Mason, P. L. Iversen, and P. L. Triozzi Active Specific Immunotherapy with a {beta}-Human Chorionic Gonadotropin Peptide Vaccine in Patients with Metastatic Colorectal Cancer: Antibody Response Is Associated with Improved Survival Clin. Cancer Res., July 1, 2002; 8(7): 2044 - 2051. [Abstract] [Full Text] [PDF]

				J.-Y. Wu, W. F. Wade, and R. K. Taylor Evaluation of Cholera Vaccines Formulated with Toxin-Coregulated Pilin Peptide Plus Polymer Adjuvant in Mice Infect. Immun., December 1, 2001; 69(12): 7695 - 7702. [Abstract] [Full Text] [PDF]

				C. Yang, W. E. Collins, J. S. Sullivan, D. C. Kaslow, L. Xiao, and A. A. Lal Partial Protection against Plasmodium vivax Blood-Stage Infection in Saimiri Monkeys by Immunization with a Recombinant C-Terminal Fragment of Merozoite Surface Protein 1 in Block Copolymer Adjuvant Infect. Immun., January 1, 1999; 67(1): 342 - 349. [Abstract] [Full Text] [PDF]